Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Nail Psoriasis
Interventions: Deucravacitinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Psoriatic Arthritis
Interventions: Secukinumab 300 mg, Secukinumab 150 mg, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 57
States / cities: Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more

Conditions: Plaque Psoriasis
Interventions: Enstilar; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Plaque Psoriasis
Interventions: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen, Clobex® Spray morning and Vectical™ Ointment evening regimen; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Evansville, Indiana + 2 more

Conditions: Psoriasis
Interventions: ABBV-157, Placebo for ABBV-157; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more

Conditions: Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis, Anxiety Disorders, Depressive Disorders, Moderate Depression, Moderate Anxiety
Interventions: Creating Health Online Course, Delayed access to Creating Health Online Course; Behavioral
Lead sponsor: Terry L. Wahls; Other
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Psoriasis
Interventions: Observational (Non-Interventional) Registry; Other
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Psoriatic Arthritis
Interventions: Telemedicine; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 89 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Psoriasis, Atopic Dermatitis
Interventions: CT-100-004-A, CT-100-004-B; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Arthritis, Psoriatic
Interventions: Placebo, Golimumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 13
States / cities: Glendale, Arizona • Mesa, Arizona • Huntington Beach, California + 10 more

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psoriasis
Interventions: Placebo, RG3421 120mg, RG3421 20mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 15
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Santa Monica, California + 11 more

Conditions: Dermatitis, Atopic
Interventions: Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Chronic Plaque Psoriasis
Interventions: alefacept, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 16 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 10
States / cities: Irvine, California • Santa Monica, California • Omaha, Nebraska + 7 more

Conditions: Plaque Psoriasis
Interventions: IDP-118 Lotion, IDP-118 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Fremont, California • Boynton Beach, Florida • North Miami Beach, Florida + 12 more

Conditions: Psoriasis
Interventions: Partial schedule of pharmacotherapeutic reinforcement, Dose control for Arm B, Standard pharmacotherapeutic protocol; Behavioral · Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2006
U.S. locations: 2
States / cities: Palo Alto, California • Rochester, New York

Conditions: Psoriatic Arthritis
Interventions: Izokibep, Placebo to izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Chronic Plaque Psoriasis
Interventions: LCD, calcipotriol; Drug
Lead sponsor: NeoStrata Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: SFA002; Drug
Lead sponsor: SFA Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Pompano Beach, Florida • Fargo, North Dakota • Philadelphia, Pennsylvania

Conditions: Psoriatic Arthritis
Interventions: Apremilast 30 mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Palm Desert, California • Brandon, Florida + 20 more

Conditions: Psoriatic Arthritis
Interventions: ACTHar; Drug
Lead sponsor: IRIS Research and Development, LLC; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Psoriatic Arthritis
Interventions: AIN457 (secukinumab), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more

Conditions: Psoriasis
Interventions: CC10004; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 3
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Plaque Psoriasis
Interventions: Elimune Capsules; Dietary Supplement
Lead sponsor: Elorac, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Chicago, Illinois • Lake Forest, Illinois • Fair Lawn, New Jersey + 1 more

Search by objective public record fields.

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study

Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

A Study of Golimumab in Participants With Active Psoriatic Arthritis

Research in Skin Inflammation

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

Safety and Efficacy of IDP-118 in Participants With Plaque Psoriasis

Conditioning, the Placebo Effect, and Psoriasis

Psoriatic Arthritis Study of Izokibep

LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis

Evaluate the Effect of Elimune Capsules